Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

  • Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives
  • The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design
  • It also affirmed Lexaria’s product superiority while also showing DehydraTECH’s potential

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time required to reach comparable maximum nicotine concentrations (“Tmax”) levels (https://cnw.fm/17JMQ).

Lexaria’s CEO, Chris Bunka, lauded his team for this achievement, especially considering they had to work without as many resources as global multi-billion-dollar behemoths. He also lauded the company’s technology, citing its potential and advantages, as demonstrated in the study.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he noted (https://cnw.fm/17JMQ).

Several intriguing data trends were observed from the study. For one, most of the subjects reported that they felt euphoric at all time points when they used Lexaria’s product. Lexaria also got the highest endorsement score, with statistical significance demonstrated at the second dosing visit. The highest percentage of users reporting that they considered the experience “pleasurable” at the 30-minute mark were also Lexaria users, and the company also scored best on the enjoyment scale.

Negative effects, meanwhile, such as nausea and severe hiccups were experienced more by the mass-market products than by the Lexaria formulation.

The study embraced a randomized, double-blind, cross-over study design involving 36 participants, all long-time heavy cigarette smokers who smoke at least ten cigarettes a day. Subjective effects, both positive and adverse, were assessed at baseline, 5 minutes, 30 minutes, and 120 minutes using a questionnaire to capture 25 different effects. All laboratory procedures for the study were conducted entirely by U.S.—based, third-party independent contract service providers (https://cnw.fm/17JMQ).

The results from this study not only validate Lexaria’s efforts but also affirm its product superiority while also showing DehydraTECH’s potential. This is a tremendous achievement for the company, given that this has been achieved in just five years. It reflects the company’s commitment to making the world a better place and its resolve to create value for its shareholders.

“We’ve always had an overwhelming determination and fierce conviction that we can make the world a better place and reduce the carnage caused by smoked cigarettes, and now we have human study data that demonstrates the advantages of DehydraTECH processed nicotine relative to the competitive landscape,” noted Mr. Bunka (https://cnw.fm/17JMQ).

For company information, visit the company’s website at www.LexariaBioscience.com 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the Canadian cannabis sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CanadianCannabisWire, text “CCWIRE” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: www.CanadianCannabisWire.com/Disclaimer

CanadianCannabisWire
Austin, Texas
www.CanadianCannabisWire.com
512.354.7000 Office
[email protected]

CanadianCannabisWire is powered by IBN

Archives

Select A Month

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000